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A
 
BSTRACT
 
The mainstay of chronic asthma management consists
of using pharmacological agents that induce broncho-
dilatation, such as short-acting 
 
β
 
-adrenergic receptor
agonists (bronchodilators or relievers), and that control
the chronic inflammatory process, such as cortico-
steroids (anti-inflammatory or controllers). Short-acting
 
β
 
-adrenergic receptor agonists are the best relievers,
whereas inhaled corticosteroids, by inhibiting eosino-
philic and lymphocytic inflammation and mediator/
cytokine expression, remain the mainstay chronic
treatment of asthma. Long-acting 
 
β
 
-adrenergic recep-
tor agonists are best used in conjunction with inhaled
corticosteroids, providing additive bronchodilatation,
better asthma control and reduced exacerbation rates
in patients with moderate to severe asthma. Slow-
release theophylline combines bronchodilator and some
anti-inflammatory effects and is best used in combina-
tion with inhaled corticosteroids. Leukotriene inhibi-
tors, by either inhibiting the effects of cysteinyl
leukotrienes or reducing their production, also cause
some bronchodilator effects with inhibition of eosino-
philic inflammation. They are effective in mild-to-
moderate asthma, but low-dose inhaled steroids are
more efficacious; leukotriene inhibitors also provide
additive effects in combination with inhaled steroids.
Increased understanding of the immunology and inflam-
matory responses has led to the identification of novel
targets and to the development of potentially new ther-
apies. These include immunologic targets, such as
those against T cells and T cell-related targets, anti-
cytokine therapies and anti-IgE approaches. New effec-
tive therapies are particularly needed for patients with
severe asthma who do not respond to currently avail-
able treatments.
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I
 
NTRODUCTION
 
Over the past decade, there have been many new
advances in the treatment of asthma, notably the intro-
duction of new drugs, both novel entities or improved
versions of established drugs, and the setting up of
national guidelines for the management of asthma.
Many of these advances in asthma have occurred on the
basis of an improved understanding of the pathophysiol-
ogy of asthma. How have any of the advances contrib-
uted to the improved well-being of patients with asthma?
The implementation of guidelines has, in particular,
made a most important impact on the management of
asthma and clear benefits have accrued from establish-
ing educational needs, increased awareness of asthma
and self-management plans.
 
1
 
 In contrast, despite these
advances, recent surveys of asthma patients indicate that
there is ongoing morbidity due to asthma within the
community.
 
2,3
 
 For example, up to 50% of patients with
asthma continue to complain of frequent nocturnal
symptoms despite being on maximal therapies. This
indicates that there is still more work to be done. It is
possible that there is still poor implementation of the
guidelines for the treatment of asthma or that the disease
may not be entirely responsive to currently available
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treatments in all patients. More efficacious treatments
that are relatively free of side-effects and well-tolerated
by patients should become available.
The increasing understanding of airway pathophysiol-
ogy has allowed the identification of new targets for the
treatment of asthma. The present article will focus on
current therapies and recent progress, as well as potential
new therapies.
 
I
 
MMUNOLOGY
 
, 
 
INFLAMMATION
 
 
 
AND
 
 
 
REMODELING
 
 
 
OF
 
 
 
THE
 
 
 
AIRWAYS
 
Much of asthma is associated with atopy, which is the
state of allergic responsiveness to commonly encoun-
tered aeroallergens. These foreign peptides are usually
taken up by specialized cells on mucosal surfaces, such
as dendritic cells, and subsequently presented to naïve
T cells. The activation of naïve T cells requires direct
signaling by two distinct pathways, first via the CD4
 
+
 
 T
cell receptor through the antigen-presenting cell (APC)-
bound antigen : major histocompatibility complex (MHC) II
complex and, second, via the costimulatory pathway
linked by the B7 family and T cell-ound CD28.
 
4
 
 T cells
stimulated via the T cell receptor in the absence of
costimulatory signaling are incapable of interleukin (IL)-2
secretion and subsequent activation and, therefore,
enter an anergic state. CD28 itself has two major
ligands: B7.1, which inhibits T helper type 2 (Th2) cell
activation and development, and B7.2, which induces
T cell activation and Th2 development. An important
third ligand, CTLA4, is expressed on activated T cells,
binds CD28 with enhanced avidity and acts as a
negative regulator of T cell function by inhibiting Th2
differentiation.
 
5
 
 In those who later develop an allergic
response, naïve T cells differentiate into the Th2 subtype.
B7/CD28-mediated costimulation may be inhibited by a
recombinant fusion protein known as CTLA4-Ig, which
binds B7 molecules with an affinity similar to membrane
CTLA
 
4
 
.
 
6
 
The chronic airway inflammation of asthma is charac-
terized by infiltration of the airway wall by diverse effector
cells, including T lymphocytes, eosinophils, monocytes/
macrophages and mast cells, and, occasionally, neutro-
phils.
 
7–10
 
 The mobilization, activation and trafficking of
these effector cells to the airway are controlled by a
complex cytokine milieu derived from activated CD4
 
+
 
 Th
cells and also from other resident airway cells, includ-
ing airway smooth muscle and epithelial cells. The Th2
cells secrete a Th2 profile of cytokines after cognate
stimulation of the naïve T cell by APC, such as the den-
dritic cell and the alveolar macrophage. Figure 1 depicts
the balance of Th1 and Th2 cell production.
The Th2 cytokines include IL-4, IL-5, IL-9, IL-10 and
IL-13 and many genetic studies have identified the Th2
cytokine gene cluster on chromosome 5q as a suscepti-
bility locus for asthma.
 
11
 
 These cytokines promote various
elements of allergic inflammation, including propagation
of the Th2 phenotype, isotype switching from IgG1 to IgE
synthesis, eosinophil mobilization, maturation and acti-
vation, mast cell activation and mucus gland hyperplasia
and secretion.
 
12
 
 Therefore, asthma has been considered
as a disease resulting from an increased activity of Th2
cells, as supported by observations that allergen-specific
Th2 cells can induce bronchial hyperresponsiveness
(BHR) and eosinophilia when transferred to naïve recipi-
ent animals.
 
13,14
 
 Furthermore, Th1 cells appear to have
an inhibitory effect on effector functions of Th2 cells.
 
13
 
In addition, the airway wall undergoes variable
chronic changes labeled as remodeling. Structural changes
include thickening of the airway smooth muscle due to
hypertrophy and hyperplasia, myofibroblast activation
with an increase in subepithelial basement membrane
collagen deposition, angiogenesis, an increase in sub-
mucosal blood vessels and an increase in goblet cell
numbers in the airway epithelium.
 
8,15–17
 
 These changes,
too, are variably influenced by certain Th2 cytokines and
certain growth factors, but the exact stimulus for the
changes in airway wall remodeling are unknown.
 
C
 
HRONIC
 
 
 
INFLAMMATION
 
, 
 
AIRWAY
 
 
 
SMOOTH
 
 
 
MUSCLE
 
 
 
AND
 
 
 
PHYSIOLOGIC
 
 
 
CHANGES
 
The exact link between the chronic inflammatory and
remodeling processes and the clinical presentation of
asthma is unclear in terms of the pathophysiologic
mechanisms and of the contribution of the components
of these processes to BHR, airway narrowing and acute
exacerbations that characterize the disease. The over-
whelming hypothesis is that these are intricately related,
such that inhibition or prevention of the inflammatory
process should improve the control of asthma, an idea
supported so far by the potent actions of topical corti-
costeroids in controlling the eosinophilic and lympho-
cytic inflammation of asthma, while being most effective
in restoring lung function and BHR. However, which
specific parts of the immunologic and inflammatory
processes are important remains to be elucidated. Indeed,
the introduction of specific blockers of certain cytokines
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in the treatment of asthma may help to elucidate the
importance of some of these processes. Another impor-
tant aspect is the finding of abnormalities of the airway
smooth muscle in asthma, such as potential changes in
phenotype with increased contractility, augmented release
of inflammatory cytokines and excessive proliferation.18,19
How these abnormalities of airway smooth muscle
contribute to BHR, airway narrowing and acute episodes
of asthma are not known. Much work is now focused
on whether there is a fundamental abnormality of the
airway smooth muscle contractile apparatus that could
account for BHR.20 Such an improvement in understand-
ing could lead to better ‘stabilizers’ of the airway smooth
muscle in asthma. The presence of increased airway
smooth muscle mass, as occurs in patients who have
died of asthma,21 may mean that there is an increased
contractile capacity of the muscle, but the rearrange-
ment of the individual components of the muscle may be
altered.22
CURRENT TREATMENTS FOR ASTHMA
Against this background, current treatments of asthma
have improved, although these changes may not have
come directly from this improved understanding of the
pathophysiology of asthma. Historically, the use of
adrenergic agonists and of corticosteroids in asthma has
been derived by serendipidity. The basic tenets under-
lying the treatment of asthma have not changed, and
β-adrenergic agonists and corticosteroids remain the
drugs most commonly used by patients with asthma for
the relief of symptoms and the control of inflammation,
respectively (Fig. 2). First, treatment aimed at controlling
symptoms with immediate reversal of symptoms of
wheeze and shortness of breath continues to be pro-
vided by short-acting β-adrenergic receptor agonists,
which can be used as needed or as regular therapy. In
patients with mild to moderately severe asthma, who
are using salbutamol 200 µg four times daily and are
not on inhaled corticosteroid therapy, there has been
no evidence of deterioration of asthma.23,24 If a patient
needs regular dosing with a short-acting β-adrenergic
receptor agonist, he/she should be established on
inhaled anti-inflammatory therapy. The use of the short-
acting β-adrenergic receptor agonist may then revert to
‘on demand’ use.
Long-acting β-adrenergic receptor agonists (salme-
terol and formoterol), by virtue of their duration of action
(12 h), can prevent symptoms, particularly nocturnal
asthma, but are used as maintainence therapy.25,26 It is
logical to use these agents in patients who need short-
acting β-adrenergic receptor agonists every 4–8 h to
Fig. 1 T helper (Th) cell acti-
vation resulting from antigen
presentation and Th1 and Th2
cytokine elaboration. APC,
antigen-presenting cell; IL, inter-
leukin; IFN-γ, interferon-γ
 
; MHC,
major histocompatibility com-
plex; TCR, T-cell receptor; Thp,
T helper progenitor.
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control symptoms; however, it is not recommended that
this treatment be used without the concomitant use of
anti-inflammatory treatment, usually inhaled cortico-
steroids. Recent evidence of an additive effect to inhaled
corticosteroids in terms of symptom control, an improve-
ment in lung function and prevention of exacerba-
tions,
 
27,28
 
 has led to a major positioning of the long-
acting 
 
β
 
-adrenergic receptor agonists as combination
therapy with inhaled steroids.
The need to control inflammation in asthma remains
important. Inhaled corticosteroids are the best anti-
inflammatory category of drugs used in the patients with
the mildest to more severe asthma.
 
29
 
 Even at the mild end
of the spectrum of the disease, benefits can be obtained
and early initiation of therapy with inhaled corticosteroids
may lead to a more beneficial response in terms of clini-
cal or lung function response.
 
30–32
 
 For example, treat-
ment of children with budesonide (400 
 
µ
 
g/day) reduced
asthma exacerbations and improved BHR to metha-
choline over a 4 year period.
 
33
 
 Whether early therapy
‘prevents’ the onset of airway wall remodeling is not an
easily answerable hypothesis. One study showed that
there was no prevention of lung function decline.
 
33
 
 The
pros and cons of treating patients with mild asthma with
long-term inhaled corticosteroid therapy have not been
sufficiently evaluated. For the control of more moderate
to severe disease, it is now emerging that the relationship
of dose to the response (measured as improvement in
lung function, or symptoms, or prevention of exacerba-
tions) is relatively shallow at the recommended middle
doses of inhaled steroids and that certainly at the high
doses the response is relatively flat.
 
34,35
 
 This observation
is very important because this allows the clinician to use
the most effective dose with a lesser risk of side-effects.
There has been some reassurance about the potential
for growth suppression in children at recommended
doses.
 
33,36
 
 Loss of bone density may occur with regular
use of high-dose inhaled steroids, but whether this is of
clinical significance is unclear.
What about other medications in asthma? Theophyl-
line is of particular interest and slow-release formulations
are now less commonly used as first-line bronchodilators
because they are relatively poor bronchodilators and, at
doses that achieve the so-called ‘therapeutic’ levels, side-
effects such as nausea and vomiting are common.
Because of the potential anti-inflammatory effects of the-
ophylline, even at doses that do not achieve therapeutic
levels, it is more useful as combination therapy with
inhaled corticosteroids in patients with moderately severe
asthma.
 
37,38
 
 Although sodium cromoglycate and nedo-
cromil sodium continue to be recommended as prophylactic
treatment and are often classified as anti-inflammatory,
 
39
 
their effectiveness as anti-inflammatory or preventive treat-
ments in mild-to-moderate asthma is small.
 
40
Fig. 2 Step-wise approach to
the treatment of asthma accord-
ing to recent guidelines. LTRA,
leukotriene receptor antagonist;
SR, slow release. The dose of
inhaled corticosteroids refers to
beclomethasone dipropionate.
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N
 
EWLY
 
 
 
INTRODUCED
 
 
 
DRUGS
 
 
 
FOR
 
 
 
ASTHMA
 
New corticosteroids
 
More potent steroids continue to be developed. Flutica-
sone propionate has a potency twofold that of bec-
lomethasone dipropionate, as demonstrated in clinical
studies.
 
41
 
 The question is whether even more potent
steroids will bring further benefits. It is unlikely that
substantially important improvements will accrue given
the relatively shallow dose–response relationship, but
there may be a reduction in the risk of systemic side-
effects. However, one practical advantage is the possi-
bility of using inhaled steroid therapy only once daily or
even less frequently. Mometasone propionate will be
introduced on the market at a once daily recommended
regimen,
 
42
 
 although other inhaled corticosteroids, such
as budesonide, may already be taken once daily for
relatively stable patients. Other corticosteroids being
developed, such as ciclesonide, are only converted to
the active moiety after deposition in the airways, which
could signify a reduction in local side-effects (e.g.
hoarse voice or loss of voice) and, possibly, in systemic
side-effects.
Research into the basic mechanisms of action of corti-
costeroids continue. Much attention has been focused on
the molecular activities of the activated glucocorticoid
receptor (GR) and on its action as a transcription factor.
The GR can either switch on the expression of inflam-
matory genes, such a secretory leukocyte proteinase
inhibitor or lipocortin-1, or switch off inflammatory gene
expression by targeting pro-inflammatory transcription
factors, such as nuclear factor-
 
κ
 
B (NF-
 
κ
 
B) and activating
protein-1 (AP-1), or members of the mitogen-activated
protein kinase (MAPK) pathways. However, in stable
asthma, we found no evidence that corticosteroids switch
off activation of NF-
 
κ
 
B,
 
43
 
 although corticosteroids may
inhibit the activation of other transcription factors. The
transactivation versus the transrepression effects of the
activated GR has been the subject of some interest
because it is thought possible to have molecules that
could have more of a transrepressive and less of a
transactivation property, which may be associated with
fewer side-effects. The more recent studies on histone
acetylation demonstrate that this effect is also impor-
tant as an anti-inflammatory effect of steroids.
 
44
 
Activated GR targets various chromatin modification
complexes, such as histone acetyltransferases, cAMP
response element-binding protein (CREB)-binding protein
(CBP)/p300 and steroid receptor coactivator (SRC)-1.
Overexpression of CBP increases the transcription
potential of activated GR, as well as its transrepressive
action of NF-
 
κ
 
B.
 
45
 
 The anti-inflammatory actions of
glucocorticoids may be potentiated by histone deacety-
lase inhibitors.
 
Combination of inhaled corticosteroids and 
long-acting 
 
β
 
-adrenergic receptor agonists
 
The superiority of concomitant treatment with low to
middle doses of inhaled corticosteroids and long-acting
 
β
 
-adrenergic receptor agonists over a high dose of
inhaled corticosteroids in the control of asthma
 
27,28
 
 has
led to the recommendation that this combined treat-
ment be used for patients with more severe asthma.
There are now preparations of these drugs available in a
single inhaler, which helps to simplify treatment and
hopefully improve adherence. Seretide
 
®
 
 (Glaxo-Smith-
Kline, Greenford, UK) is a combination of fluticasone
propionate and salmeterol,
 
46
 
 whereas Symbicort
 
®
 
 (Astra-
Zeneca, Herts, UK) is budesonide combined with for-
moterol,
 
47
 
 available at several fixed-dose combinations.
One issue with this combined inhaler is whether it should
be prescribed to patients at the first assessment or
whether only inhaled steroid therapy should be tried
first to observe the response, with the long-acting 
 
β
 
-
adrenergic receptor agonist only added when symptoms
or lung function do not improve on inhaled cortico-
steroids alone. This combination therapy may become
the treatment of choice for patients with moderately
severe asthma.
Is there is a molecular basis for this positive inter-
action between these two mainstay drugs for asthma?
Positive interactions between corticosteroids and long-
acting 
 
β
 
-adrenergic receptor agonists include the effects
of corticosteroids in increasing 
 
β
 
-adrenergic receptor
expression through increased gene transcription.
 
48
 
 In
addition, 
 
β
 
-adrenergic receptor agonists may also
potentiate the molecular mechanisms of corticosteroid
action by increasing the translocation of the GR to the
nucleus, which could translate into a greater effect of
corticosteroids.
 
49
 
 For example, a combination of β-
adrenergic receptor agonist with fluticasone suppressed
interleukin (IL)-8 production from airway smooth muscle
cells more than either of these agents on their own.50
Unravelling these mechanisms may provide other novel
drugs.
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Leukotriene inhibitors
Introduced over the past 7–10 years, montelukast, pran-
lukast and zafirlukast are leukotriene receptor antago-
nists that block the effects of cysteinyl-leukotrienes
released in the airways of patients with asthma.51 The
development of these agents was made possible because
of the discovery of cysteinyl-leukotrienes as being the
major active ingredient of the slow-reacting substance A
released from allergen-challenged sensitized lungs.
Cysteinyl-leukotrienes contribute to bronchoconstriction,
cough, mucus production, airway edema and eosinophil
recruitment and are, therefore, important mediators of
asthma. The leukotriene inhibitors induce bronchodilata-
tion and reduce the number of eosinophils in sputum
and in the bronchial submucosa. Leukotriene inhibitors
have been evaluated extensively in clinical trials in
patients with persistent asthma and have been shown to
be efficacious and have a good safety profile.52,53 In
patients with milder persistent asthma in whom disease
control is not achieved with inhaled β-adrenergic recep-
tor agonist use alone, low-dose inhaled steroid therapy
is more effective. Inhaled corticosteroid therapy provided
better lung function and quality of life, as well as reduced
symptoms, night awakenings and need for rescue β-
adrenergic receptor agonist use.54,55 The rate of exacer-
bations was similar between patients treated with inhaled
steroids or antileukotrienes. In patients with mild persist-
ent asthma, leukotriene inhibitors should be considered
if patients cannot tolerate inhaled corticosteroid therapy
or have trouble using their inhaler devices. The added
benefit of leukotriene inhibitors to inhaled corticosteroids
has also been demonstrated,54,56 including a benefit in
the reduction of exacerbations in asthmatic children.57
The effectiveness of this approach has been compared
with the addition of a long-acting inhaled β-adrenergic
receptor agonist and the latter has been shown to be
superior in terms of lung function outcomes.58 One of
the recommendations is that leukotriene inhibitors be
tried as additive therapy to inhaled corticosteroid therapy
in moderate persistent asthma. If an antileukotriene is
chosen as the next line of treatment, a therapeutic trial of
4 weeks should be undertaken.
Potential new drugs or approaches to asthma
The pharmaceutical industry has been very active in
developing new targets for the treatment of asthma and,
armed with advances in cell and molecular biology, it is
now possible to target the effects of cytokines or other
similar proteins involved in asthma12 or to manufacture
anti-inflammatory cytokines using recombinant technol-
ogy. There are many potential targets (Table 1). A more
detailed account of the immunologic targets, particularly
those against T cells and T cell-related targets, has been
published recently.59
BLOCKING THE EFFECTS OF IL-4
Interleukin-4 has a central role in Th cell development as
a potent inducer of Th2 maturation from the naïve
T lymphocyte. In addition, IL-4 induces the isotype switch
necessary for IgE synthesis and upregulates IgE recep-
tors60 and vascular cell adhesion molecule-1 (VCAM-1)
Table 1 New strategies for inhibition and prevention of
allergic asthma
1. Prevention of T cell activation
Anti-CD4
CTLA-4
Cyclosporine A
FK506
Methotrexate
Azothiaprine
Suplatast tosilate
2. Prevention or reversal of Th2 expression
Inhibition of Th2 cytokines/phenotype
Soluble IL-4Rα
Rhu IL-4 mutant protein
STAT6 inhibition
Anti-IL-5 monoclonal antibody
GATA-3 inhibition
Soluble IL-13Rα
Promotion of Th1 cytokines/phenotype
IFN-γ
IL-12
IL-18
CpG vaccines
3. Inhibition of downstream mediators
Anti-inflammatory cytokines
IL-10
IL-1Rα
Inhibition of eosinophil migration and activation
CCR3 antagonist/antisense
VLA4 inhibitor
ICAM-1 inhibitor
Met-RANTES
Met-Ckβ7
IgE inhibition
Monoclonal anti-IgE
Th, T helper cell; IL, interleukin; IL-4Rα, IL-4 receptor α subunit;
STAT, signal transducers and activators of transcription; IFN, interferon;
CpG, cytosine–guanosine dinucleotide motifs; VLA4, very late antigen-4;
ICAM-1, intercellular adhesion molecule-1.
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expression on vascular endothelium, thus facilitating
endothelial passage and accumulation of eosinophils.
Therefore, IL-4 is an attractive target to inhibit, resulting
in downregulation of Th2 activation. Anti-IL-4 mono-
clonal antibody treatment of mice prior to allergic
sensitization markedly reduces IgE synthesis,61 but does
not appear to inhibit airway eosinophilia or BHR.62 A
recombinant soluble IL-4 receptor (sIL-4R) has been
designed as a mimic of the cell-surface receptor that
binds and sequestrates free IL-4,63 but because these
soluble receptors lack transmembrane and cytoplasmic
domains, they act as an IL-4 receptor blocker. In murine
studies, sIL-4R reduces allergen-specific IgE responses,
airway hyperresponsiveness, VCAM-1 expression and
eosinophil accumulation.63 Preliminary human asthma
studies with single doses of sIL-4R have shown accept-
able tolerability, improvement in lung function and a
reduction in rescue β-adrenergic receptor agonist
requirement.64 In addition, a trend towards a reduction
in serum eosinophil cationic protein levels and in
exhaled nitric oxide levels64 suggests suppression of
inflammation by this agent. In a phase I/II randomized
double-blind controlled study, sIL4-R was administered
for 12 weeks by nebulization in patients with moderately
severe asthma. Inhaled steroid therapy was stopped and
the patients on active treatment failed to deteriorate and
improved (an increase of 19% over placebo-treated
patients) compared with those on placebo, whose forced
expiratory volume in 1 s deteriorated by 13%.65
It is likely that the relatively small beneficial effect of
inhibiting IL-4 with sIL-4R is due to the fact that IL-13,
which is not targeted by sIL-4R, also has overlapping
biological roles with IL-4. Both IL-4 and IL-13 share a
common pathway of activation, through the IL-4Rα. A
more efficient way of targeting both IL-4 and IL-13 is to
inhibit IL-4Rα, using humanized monoclonal antibodies
or small blocking molecules.
BLOCKING THE EFFECTS OF IL-5
Interleukin-5 is important for eosinophil maturation and
mobilization from the bone marrow.66 Mepolizumab, an
anti-IL-5 antibody, blocked allergen-induced lung eosino-
philia, without changing the expression of both the early
and late phase responses,67 whereas in a clinical trial
(GSK, data on file, 2000) of moderately severe sympto-
matic asthma, mepolizumab had no effect on symptoms
and lung function. This antibody is no longer undergoing
further clinical development. These negative results have
been taken by some to indicate that targeting eosino-
philic inflammation may not be a useful therapeutic
approach. However, an alternative explanation is that
IL-5 is not the only cytokine necessary for the recruitment
and activation of eosinophils; indeed, the chemokine
that is selective for eosinophils, namely eotaxin, may
also play an important role in airway tissues for chemo-
taxis and activation of eosinopjhils. Antagonists of the
chemokine receptor CCR3, which is activated selectively
by eotaxin with specific effects on eosinophils, are being
developed for asthma therapy. The adhesion of cells,
such as eosinophils, to the endothelium and its activa-
tion can be targeted by inhibiting adhesion molecules
using the antibody approach, such as anti-VCAM anti-
bodies. Therefore, it is likely that only an anti-IL5
approach may not be sufficient to completely inhibit
eosinophilic inflammation and activation and that it may
be necessary to combine this approach together with a
CCR3 chemokine receptor antagonist, for example.
ANTI-IGE THERAPY
Omalizumab is an anti-IgE recombinant humanized
monoclonal antibody that is currently being developed
for the treatment of severe allergic asthma. It forms
complexes with free IgE, thereby blocking the interaction
of IgE with high-affinity IgE receptors on mast cells and
basophils, thereby impeding the recognition of allergen
and activation of the cells. Treatment with omalizumab
reduces the number of high-affinity IgE receptors on
circulating basophils.68 Omalizumab attenuated the early
and late-phase response to allergen in allergic asth-
matics.69,70 In studies performed in moderate to severe
allergic asthmatics, omalizumab, administered sub-
cutaneously once every 2 or 4 weeks, led to improved
asthma control with fewer exacerbations, together with a
reduction in the maintenance dose of inhaled cortico-
steroids.71–73 A meta-analysis of three studies reported
that omalizumab halved the rate of asthma exacerba-
tions and improved asthma control in patients at high
risk of asthma-related morbidity and mortality.74 The
treatment was well tolerated, with an adverse event
profile similar to that of placebo. Omalizumab is not
currently licensed, but it will be useful in treating patients
with severe allergic asthma. These studies also demon-
strate a major contribution of IgE to the pathophysiology
of severe asthma. This is the first monoclonal antibody
treatment for asthma and the cost of manufacturing this
antibody may be an important determinant of its use.
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TARGETTING T CELLS: RESTORING THE 
IMBALANCE OF TH/TH2
Inhibitors of T cells with immunosuppresants, such as
cyclosporine A and methotrexate, have been used in the
treatment of steroid-dependent asthma as corticosteroid-
sparing agents.75,76 These drugs inhibit T cell growth by
blocking the G0 phase through inhibition of T cell growth
factors, such as IL-2. Although cyclosporine A has been
shown to inhibit the late-phase response in patients with
asthma,77 the effects of T cell inhibitors and immuno-
suppressants on an allergic model of inflammation has
been disappointing.78,79 It is possible that this is due to
the inhibition of both Th1- and Th2-derived cytokines
and, therefore, this may not lead to an improvement in
asthma.
A more specific approach to the therapy of asthma
involves the suppression of the overexuberance of the
Th2 response, such as inhibiting the effects of IL-4 and
IL-5. Suplatast tosilate is a novel immunomodulator
developed in Japan that selectively prevents the release
of IL-4 and IL-5 from Th2 cells and can reduce bronchial
eosinophilia in animal models of BHR.80 In patients with
moderately severe asthma, suplatast tosilate provides
continuing control of asthma despite a reduction in the
maintenance dose of inhaled corticosteroids.81 Such an
approach may be generally more acceptable because it
targets cytokines comprising the Th2 spectrum. Another
approach would be to interfere with the transcriptional
activation of the Th2 cytokines. Signal transducers and
activators of transcription (STAT)-6 belongs to a family of
transcription factors that is activated by IL-4 and IL-13
and is important in the differentiation of Th2 cells.82
GATA3 is a downstream transcription factor of STAT-6
and is also essential for Th2 development. Thus, inhibi-
tors of STAT-6 would block Th2-mediated deleterious
effects.
Specific immunotherapy is a technique aimed at the
induction of specific unresponsiveness, or anergy, in
peripheral T cells to peptide epitopes and works through
the production of IL-10.83 Novel forms of immunotherapy
are being tried, such as the development of peptides that
can block the allergic immune response. Peptide immuno-
therapy may be considered as a refinement of specific
immunotherapy, with the object of inhibiting T cell activa-
tion independent of IgE-mediated reactions. Vaccina-
tions, such as boosting immunity against tuberculosis,
can alter the balance of Th1 versus Th2 in favor of Th1
response, which could prevent the development or
reduce the severity of allergic disease, including asthma.
DNA vaccines containing the cytosine–guanosine dinu-
cleotide motifs (CpG) can induce Th1 responses, which
prevent Th2 responses.84
USING IL-12 TO INHIBIT TH2 ACTIVATION
Interleukin-12 is produced by APC and enhances the
growth of activated T and NK cells, stimulating them to
produce interferon (IFN)-γ.85,86 Interleukin-12 also pro-
motes the differentiation of IFN-γ-producing T cells and
inhibits the differentiation of T cells into IL-4-secreting
cells.87 Thus, IL-12 can regulate Th1 cell differentiation
while suppressing the expansion of Th2 cell clones by
early priming of undifferentiated Th0 cells for IFN-γ
secretion. In murine asthma models, administration of
IL-12 leads to a reduction in allergen-specific IgE levels,
ablation of airway hyperresponsiveness and inhibition of
eosinophil recruitment.88 This protective role may only
be conferred when acting synergistically with IL-18. In
therapeutic trials, IL-12 levels increased during cortico-
steroid therapy89 and during specific immunotherapy.90
In a phase I trial of IL-12 in asthma, a significant
reduction of peripheral eosinophils and trend towards a
reduction in airway eosinophils was observed without
any effect on allergen-induced early or late-phase
responses.91 Interleukin-12 has proved a useful adjunct
to cancer chemotherapy by induction of a protective Th1
response, but significant toxicity, including arrhythmias,
liver function abnormalities and flu-like illness, will limit
its potential usefulness in asthma.
RESTORING GLUCOCORTICOID RESPONSIVENESS
The proposed definition of difficult therapy resistant
asthma rests on the therapeutic response of asthmatic
patients to inhaled or oral corticosteroid therapy.92
Difficult asthma may be viewed as a disease that
responds suboptimally to inhaled or oral corticosteroids,
thus necessitating high doses of these treatments at the
risk of side-effects. Much work has focused on ‘steroid-
resistant’ asthma, but the response to corticosteroids is
relative to the doses of corticosteroids used. In the
‘steroid-resistant’ asthmatic, the inflammatory infiltrate
of eosinophils in the airway submucosa is similar to that
of the steroid-sensitive patient; in addition, there is
similar expression of the Th2 cytokines IL-4 and IL-5.93
However, corticosteroid treatment does not cause a
reduction in eosinophils or suppression of expression of
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IL-4 and IL-5 mRNA in the airway submucosa of steroid-
resistant asthmatics. levels of IL-12 mRNA did not
change with corticosteroid therapy in steroid-resistant
asthma, although they were increased in corticosteroid-
sensitive asthmatics. Corticosteroids also do not inhibit
the ex vivo proliferation of peripheral blood T cells of
steroid-resistant asthmatics.94 A reduction in the number
of GR available for binding to DNA in steroid-resistant
asthmatics may be attributed to an increased activation
of the transcription factor AP-1.95
The mechanisms underlying steroid-resistant asthma
may shed light on those underlying difficult asthma. Cir-
culating mononuclear cells of patients with deteriorating
asthma on exposure to allergen show a decreased binding
affinity of corticosteroid receptors, which recovers on
treatment with oral corticosteroids.96 A decreased binding
affinity of circulating mononuclear cells is also observed
in patients with severe asthma on long-term oral cortico-
steroids, but this is not secondary to the effect of long-
term treatment with oral corticosteroids. Drugs that may
reverse the partial lack of response of corticosteroids in
severe asthma may be beneficial. Thus, p38 MAPK inhib-
itors can reverse combined IL-4 and IL-2-induced reduc-
tion in the affinity of corticosteroid receptors, possibly
through inhibition of phosphorylation of residues in the
GR.97 Inhibitors of p38 MAPK are under development98
and may be useful in restoring steroid responsiveness.
However, it is not known to what extent p38 MAPK are
involved in steroid responsiveness in asthma.
There are few data regarding the state of the GR in the
airways and their properties. The GR are particularly well
expressed in the airway epithelial cells of non-asthmatics
and mild asthmatics99 and these cells may well reflect the
responsiveness of the airways to corticosteroid therapy,
because the epithelium is exposed to the highest concen-
trations of topical corticosteroids. The translocation of
GR receptors to the nucleus on receptor activation may
be impaired in corticosteroid-dependent asthma, together
with a reduced recruitment of histone deacetylase by
corticosteroids. We have recently found that patients with
corticosteroid-dependent severe asthma may fall into the
category of either those with a problem of receptor trans-
location or those with defective histone deacetylase activ-
ity (I Adcock et al., unpubl. obs., 2001). These potential
mechanisms of corticosteroid dependence or resistance
may also underlie the steroid non-responsiveness found
in patients with chronic obstructive pulmonary disease.100
Alternative splicing involving exon 9 of the GR gene
gives rise to two homologous mRNA and protein isoforms,
termed GRα and GRβ.101 The GRβ does not bind GR or
transactivate target genes, but may act as a dominant
negative inhibitor of GRα activity through mechanisms
involving transcriptionally impaired GRα-GRβ hetero-
dimers. An association between elevated GRβ expression
and relative steroid resistance in vitro and, clinically, with
steroid resistance, near fatal and fatal asthma in vivo has
been reported.101–103 However, other studies have not
found any differences in the expression of GRβ in corti-
costeroid-dependent asthmatics.104
PHOSPHODIESTERASE 4 INHIBITORS
The second messenger cAMP relaxes airway smooth
muscle, inhibits the actions of immune and inflammatory
cells and may modulate neural activities.105 Elevating the
cellular concentrations of cAMP can be achieved by
inhibiting the metabolism of cyclic nucleotide phos-
phodiesterases (PDE), enzymes that hydrolyse AMP to its
inactive 5′-nucleotide product. With particular reference
to asthma, one PDE isoenzyme, namely PDE4, is a
predominant cAMP-metabolizing isozyme in inflam-
matory cells, immune cells and airway smooth muscle.
Thus, it was rational to develop PDE4 inhibitors for the
treatment of asthma. Many pharmaceutical companies
have development compounds with PDE4 inhibitory
activities. Phosphodiesterase 4 inhibitors attenuate the
late asthmatic response to inhaled allergen in patients
with mild asthma.106 SB 207499 and roflumilast inhibit
exercise-induced asthma. In preliminary studies,
SB 207499 improved pulmonary function tests in
patients with mild to moderate asthma, with sustained
improvement over 12 months.107 Although these results
have been encouraging, other compounds have been
less promising and there is still the problem of nausea
and vomiting, which can limit the doses that can be
administered. Phosphodiesterase 4 inhibitors may be
more useful in the treatment of chronic obstructive
pulmonary disease.108
SIDE-EFFECTS FROM NOVEL THERAPIES
The advent of new biology has made it possible to
increase the armamentarium of therapeutic drugs. From
using small molecule receptor antagonists or enzyme
inhibitors, we can now use antibodies to block the effects
of certain cytokines or administer therapeutic recom-
binant cytokines. In addition, it is possible to block the
effect of certain mediators by genetic therapy, including
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the antisense oligonucleotide approach. The potential
for side-effects of these approaches is an on-going
worry. Side-effects may be associated with the mode of
approach itself, such as anaphylaxis to foreign protein or
peptide, or to the production of high molecular weight
antigen–antibody complexes that could lead to deposi-
ton in the glomeruli. Side-effects may also be due to
suppressing or mimicking the effects of a particular
cytokine, which may depend on whether the given
cytokine has any ‘physiologic’ role or is involved in
normal immune defences.
The only recent experience in asthma has been with
the anti-IgE antibody omalizumab. This has been encour-
aging so far, with no increased incidence of serious side-
effects when compared with placebo.71–73 No evidence of
anaphylaxis or an increased incidence of parasitic infec-
tions was observed. A longer experience has been
obtained with the anti-tumor necrosis factor (TNF)-α
antibodies, such as etanercept,109 a recombinant human
soluble fusion protein of TNF-α type II receptor and
IgG1, or infliximab, a humanized, mouse-derived,
genetically engineered monoclonal antibody to TNF-α
used for the treatment of chronic rheumatoid arthritis.
Anti-TNF-α therapy has now been associated with activa-
tion of latent tuberculosis109 and four cases of a syn-
drome resembling systemic lupus erythematosis have
also been reported.110 These side-effects may be related
to the important role of TNF-α in various body functions,
such as protection against infection and tumor progres-
sion. As a general point, it also serves to indicate that vig-
ilance in the long term is needed with these new
therapeutic approaches.
CONCLUSIONS
There have been important developments in the therapy
of asthma over the past 10 years, with the introduction
of improved corticosteroids and β-adrenergic broncho-
dilators and of new entities such as leukotriene inhibi-
tors. We have a better idea of how to use these agents
most effectively in clinical practice. Do we need new
drugs, which can only be developed at considerable
costs? Yes. There are still many unmet needs in asthma,
which will be partly solved by the introduction of newer
agents. The present review has not been exhaustive in
including all the potential new therapies or strategies
currently being tried in asthma patients. Many more
targets are available because of current research into
basic mechanisms. One particular group of asthmatics
in need of better therapies is those with severe difficult-
to-treat asthma. The addition of new drugs will hopefully
lead to a larger proportion of asthmatics achieving
better control of their asthma. This may also provide a
better choice of anti-asthma drugs available and the
specificity of certain drugs may also mean that certain
groups of asthmatics may respond better. Pharmaco-
genomic analysis may help to screen the type of patient
who may or may not respond best to certain medica-
tions, which would represent a great improvement in the
management of the patient.
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